SynBio7: Bio-Patching and Hotfixes: Synthetic Biology in Regenerative Medicine (v1.1)
Regenerative medicine deals with the "process of replacing, engineering or regenerating human or animal cells, tissues or organs to restore or establish normal function." This field holds the promise of engineering damag
The US regenerative medicine market is poised for significant expansion, primarily fueled by increased government funding (such as from the NIH and BARDA) and favorable regulatory policies. Moreover, private investments and partnerships between biotech companies and research institutions have played a vital role. As a leading global player in this field, the US is at the forefront of R&D, with numerous groundbreaking therapies and treatments being developed and commercialized.
Although great strides have been made to prolong life, we have not yet mastered ways to improve it. We often spend the last decade of our lives managing chronic conditions like Alzheimer's, diabetes, and chronic back pain. In this essay, we will look particularly at developments in the repair of hearing, new efforts to address aging and longevity, and briefly touch on tissue and organ/organoid engineering applying synthetic biology (SynBio).
Restoring Hearing through Gene Editing
In a previous essay, I detailed how hearing works. Today, a third of seniors suffer from some degree of hearing loss, and an increasing number of young people are experiencing early deficits due to high-noise exposure from earbuds and other audio devices. Beyond environmental factors, genetic disorders represent a critical area where synthetic biology—more specifically, gene editing and therapy—can offer a cure.
Usher syndrome is a genetic condition that results in both hearing loss and progressive blindness. Individuals are born with the mutated genes but are often not diagnosed until childhood or adolescence; it accounts for half of all concurrent deaf-blind cases. A number of pioneering companies are working on solutions. Editas Medicine, co-founded by Nobel laureate Jennifer Doudna alongside famed biologists George Church and Feng Zhang, is developing CRISPR-based gene editing therapies targeting these exact genetic defects. The potential to restore both sight and hearing using a single molecular intervention is enormous.
Engineering Longevity: The Cellular Hallmarks of Aging
The study of aging has become an increasingly fertile field of research. The more deeply we understand normal biological aging, the more opportunities synthetic biologists have to intervene. Science currently identifies several distinct cellular mechanisms that drive aging:
Cellular senescence: The point at which cells permanently cease to divide but remain metabolically active, often causing inflammation.
Mitochondrial dysfunction: When the cellular organelles responsible for producing energy degrade and fail to function properly.
Loss of proteostasis: The disruption of the precise coordination between molecular machineries that assist a protein from its conception to its demise.
Epigenetic alterations: Age-related changes in gene expression that alter how cells read DNA, harming fundamental cellular functions.
Telomere attrition: The progressive shortening of chromosome tips, which limits the number of times a cell population can safely divide.
Genomic instability: The accumulation of frequent genetic mutations over time.
Altered intercellular communication: Changes in the signaling pathways between cells, leading to chronic inflammation and tissue degradation.
Stem cell exhaustion: The decline in both the absolute number and the self-renewal capacity of vital stem cell niches.
Synthetic biologists are actively researching how to engineer longevity directly into cells. Around 2020, a research team at the University of California San Diego identified two distinct paths that cells follow as they age. This process can be likened to a car wearing out either due to engine deterioration or transmission wear, but rarely both simultaneously.
Building upon this knowledge, they used synthetic biology to take the research a step further. They engineered a synthetic gene circuit that acts as a biosynthetic "clock," keeping cells cycling dynamically between these two detrimental "aged" states. This gene oscillator periodically switches the cell’s aging mechanism, preventing prolonged commitment to either destructive pathway and effectively slowing down cellular degeneration. While this remains a brilliant proof-of-concept conducted in yeast cells, it opens the door to entirely new ways of thinking about human longevity.
Tissue and Organ Engineering
Tissue engineering is another ripe area of research benefiting from synthetic biology. The discipline aims to restore, maintain, improve, or replace various types of biological structures. Today, SynBio focuses primarily on engineering cells to perform highly customized functions, which can then be used to grow custom extracellular matrices. Scientists are also using SynBio to design inexpensive, highly effective biosensors and biocompatible materials for advanced medical implants.
The need for functional organs is staggering. At any given time, there are between 70,000 and 100,000 people on the national organ transplant list in the United States, and many die waiting for a donor. The history of transplantation is a timeline of extraordinary milestones:
1954: First successful kidney transplant
1963: First liver and lung transplants
1966: First pancreas transplant
1967: First heart transplant
1970s: Development of successful bone marrow transplantation
1988: First transplant of umbilical cord blood
The next frontier lies in organoids—tiny, three-dimensional tissue cultures derived from stem cells. They open up the incredible possibility of creating individualized, complex collections of cells that precisely mirror a patient’s own native tissues. While full organ and organoid engineering are extraordinarily complex topics beyond the scope of this piece, the active SynBio research happening in this space promises to rewrite the future of medicine.
Want to Read on?
Comments